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Background and purpose: The prevalence and duration of non-motor symp-
toms (NMS) in prodromal Parkinson’s disease (PD) has not been extensively
studied. The aim of this study was to determine the prevalence and duration
of prodromal NMS (pNMS) in a cohort of patients with recently diagnosed
PD.
Methods: We evaluated the prevalence and duration of pNMS in patients
with early PD (n = 154). NMS were screened for using the Non-Motor Symp-
tom Questionnaire (NMSQuest). We subtracted the duration of the presence
of each individual NMS reported from the duration of the earliest motor
symptom. NMS whose duration preceded the duration of motor symptoms
were considered a pNMS. Individual pNMS were then grouped into relevant
pNMS clusters based on the NMSQuest domains. Motor subtypes were
defined as tremor dominant, postural instability gait difficulty (PIGD) and
indeterminate type according to the Movement Disorder Society Unified
Parkinson’s Disease Rating Scale revision.
Results: Prodromal NMS were experienced by 90.3% of patients with PD
and the median number experienced was 4 (interquartile range, 2–7). A gender
difference existed in the pNMS experienced, with males reporting more sexual
dysfunction, forgetfulness and dream re-enactment, whereas females reported
more unexplained weight change and anxiety. There was a significant associa-
tion between any prodromal gastrointestinal symptoms [odds ratio (OR), 2.30;
95% confidence interval (CI), 1.08–4.89, P = 0.03] and urinary symptoms
(OR, 2.54; 95% CI, 1.19–5.35, P = 0.016) and the PIGD phenotype. Further
analysis revealed that total pNMS were not significantly associated with the
PIGD phenotype (OR, 1.10; 95% CI, 0.99–1.21, P = 0.068).
Conclusions: Prodromal NMS are common and a gender difference in pNMS
experienced in prodromal PD may exist. The PIGD phenotype had a higher
prevalence of prodromal gastrointestinal and urinary tract symptoms.
Introduction
Clinically, Parkinson’s disease (PD) has been defined
by the presence of motor deficits such as bradykinesia,
tremor, rigidity and postural instability [1]. However,
patients with PD also experience a variety of other
non-motor symptoms (NMS) such as mood disorders,
autonomic disturbances, cognitive impairment and
sleep dysfunction throughout their disease trajectory.
Non-motor symptoms can precede motor symptoms,
indicating that a prodromal symptomatic stage exists
in PD. The presence of hyposmia, constipation,
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depression and idiopathic rapid eye movement sleep
behaviour disorder are well-established symptoms that
significantly increase the risk of development of PD [2].
The emerging concept of a prodromal phase of PD
has led the International Parkinson and Movement
Disorder Society task force to propose a new defini-
tion of PD; this definition would not base the diagno-
sis solely on motor symptoms but would also
incorporate NMS [3]. However, there is a paucity of
research investigating the frequency and time of onset
of NMS before the onset of the motor phase of PD.
Furthermore, little is known about the relationship
between particular clusters of prodromal NMS
(pNMS) and the development of subsequent PD
motor phenotypes, i.e. tremor dominant (TD), postu-
ral instability gait difficulty (PIGD) or indeterminate
type [4].
We aimed to explore the frequency and time of
onset of NMS before motor symptoms (pNMS) and
the role of gender on pNMS experienced. We hypoth-
esized that distinct clusters of pNMS would be associ-
ated with PIGD motor phenotype.
Methods
Patient eligibility criteria and recruitment
Patients with recently diagnosed PD from Newcastle
upon Tyne and Gateshead were invited to take part in
the study between June 2009 and December 2011 as
part of the Incidence of Cognitive Impairment in
Cohorts with Longitudinal Evaluation-Parkinson’s
Disease (ICICLE-PD) study [5].
All participants were diagnosed by a movement dis-
orders specialist according to the UK Brain Bank crite-
ria [1]. Exclusion criteria comprised the following:
drug-induced parkinsonism secondary to exposure to
dopamine receptor blocking agent at the onset of symp-
toms; vascular parkinsonism; and atypical forms of
parkinsonism such as progressive supranuclear palsy,
multiple system atrophy or corticobasal degeneration,
according to accepted diagnostic criteria [6]. Partici-
pants were also excluded if they had insufficient work-
ing knowledge of English, defined as being unable to
perform the assessments and questionnaires in the opin-
ion of the assessor, or significant memory impairment
or dementia at presentation, defined by a Mini-Mental
State Examination score <24, fulfilling DSM-IV criteria
for dementia [7] or Movement Disorder Society criteria
for Parkinson’s disease dementia [8].
The study was approved by the Newcastle and
North Tyneside Research Ethics Committee and per-
formed according to the Declaration of Helsinki. All
participants provided informed written consent.
Assessments
Participants with PD were rated for disease severity
by Hoehn & Yahr staging and motor severity using
the Movement Disorder Society Unified Parkinson’s
Disease Rating Scale part III. Motor subtypes were
defined as TD, PIGD and indeterminate type accord-
ing to the methods described by Stebbins et al. [9].
Due to the small numbers with indeterminate motor
phenotype in the cohort, only comparisons between
motor subtype of TD and PIGD were conducted.
Levodopa equivalent daily dose (LEDD) was calcu-
lated for all dopaminergic medications using methods
described by Tomlinson et al. [10].
Global cognition was assessed using the Mini-Men-
tal State Examination and Montreal Cognitive Assess-
ment. Depressive symptoms were also assessed using
the Geriatric Depression Scale-15.
Assessment of non-motor symptoms and prodromal
non-motor symptoms
Participant NMS burden was assessed at the initial
patient screening visit using the Non-Motor Symp-
tom Questionnaire (NMSQuest) [11]. The NMSQuest
is a 30-item questionnaire that comprises 10
domains of NMS: gastrointestinal (GI) symptoms,
urinary tract symptoms, sexual function, cardiovas-
cular issues, depression/anxiety, sleep problems/fa-
tigue, pain and a number of other complaints such
as weight loss. A positive response about the
presence of an NMS on the screening questionnaire
elicited a further question about the estimated dura-
tion of the NMS symptom.
In order to determine the presence or absence of
pNMS, we subtracted the duration of the presence of
each individual NMS reported from the duration of
earliest motor symptom. NMS whose duration pre-
ceded the duration of motor symptoms were consid-
ered a pNMS, whereas NMS that occurred after
motor symptom onset were not classified as pNMS.
The presence and duration of each NMS in excess of
the duration of motor symptoms were recorded as a
pNMS in months.
Individual pNMS symptoms were further classified
into seven distinct non-motor subtypes based on the
symptom domains covered in the NMSQuest. These
were GI symptoms, urinary tract symptoms, sexual
dysfunction, cardiovascular symptoms, neuropsychi-
atric and cognitive symptoms, sleep dysfunction symp-
toms and miscellaneous symptoms. In order to be
included in a prodromal non-motor subtype, a partici-
pant had to have at least one pNMS consistent with
that NMS domain.
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Statistical analysis
Statistical analyses were performed using SPSS soft-
ware (Version 22, IBM Corp., Armonk, NY, USA).
Data were assessed for normality using Kolmogorov–
Smirnov tests. The mean and SD were computed for
parametric variables, and the median and interquartile
range for non-parametric variables. Continuous and
count data were compared using the parametric (t-
test) or non-parametric (Mann–Whitney U-test) test
as appropriate and categorical data were compared
with chi-squared tests.
Hierarchical logistic regression was used to deter-
mine significant predictors of PIGD motor phenotype.
Backwards stepwise logistic regression was used to
produce a basic model of predictors involving age,
gender and LEDD. Non-significant predictors were
excluded. Significant predictors were then included to
give a basic model and total pNMS and pNMS
domains (present or absent) were then individually
added to the model. P < 0.05 was deemed to be sig-
nificant for all analyses.
Results
A total of 154 participants with a diagnosis of idio-
pathic PD were identified from the ICICLE-PD
cohort (Table 1). Participants had a mean age of
66.4  10.4 years and had a median PD duration of
4.7 months [64.9% (n = 100) were male}.
The presence or absence of pNMS was calculated
[139 (90.3%) participants experienced pNMS]
(Table 2). The median number of pNMS experienced
by the patients with PD was 4 (interquartile range, 2–
7). The most common individual pNMS experienced
were as follows: hyposmia (39.6%), forgetfulness/
memory complaints (36%), sialorrhea (33.8%), uri-
nary urgency (30.2%) and anxiety (30.2%) (Table 2).
Gender differences in pNMS experienced were observed,
with males reporting significantly more sexual dys-
function (22% vs. 3.7%, respectively, P = 0.003), for-
getfulness (38% vs. 22.2%, respectively, P = 0.046)
and dream re-enactment (29% vs. 14.8%, respectively,
P = 0.049) compared with female participants
(Table 2). Conversely, females reported significantly
greater unexplained weight change (13% vs. 4%,
respectively, P = 0.039) and anxiety (37% vs. 22%,
respectively, P = 0.046).
Individual pNMS symptoms were classified into
pNMS domains. The most frequent pNMS domains
were GI tract (67.5%), sleep (52.6%), urinary tract
(42.2%), cardiovascular system (32.5%) and miscella-
neous systems (22.1%) (Table 3). In terms of the med-
ian duration of pNMS preceding motor symptom
onset, sleep dysfunction (66 months), sexual dys-
function (60 months) and GI tract symptoms (59
months) had the longest latency period (Table 3).
When pNMS were grouped into symptom clusters,
males experienced significantly more symptoms related
to sexual problems compared with female participants
(26% vs. 5.6%, respectively, P = 0.002, Table 3).
Females experienced significantly more miscellaneous
symptoms compared with male participants (40.7%
vs. 19%, respectively, P = 0.004).
Prodromal NMS differences between motor pheno-
types were then evaluated (Table 4). Participants clas-
sified as having PIGD were significantly older than
those with TD subtypes (68.4  9.2 vs. 63.6  11
years, respectively, P = <0.01; Table 4). The Geriatric
Depression Scale-15 scores were slightly higher for the
PIGD subtype compared with the TD subtype
(3.12  2.4 vs. 2.27  2.3, respectively, P = 0.01), but
were still below the cut-off (≥5) for possible depression
in all subtypes. Participants with PIGD subtype were
prescribed significantly higher doses of LEDD
Table 1 Characteristics of patients with Parkinson’s disease (PD)
(n = 154)
Variable
Gender (male/female) 100 (64.9)/54 (35.1)
Age (years) 66.4 (10.4)
Duration of PD (months) 4.7 (2.6–8.1)
MDS-UPDRS III score 26.9  12.1
H&Y staging 2.0  0.7
H&Y stage
I 35 (22.7)
II 88 (57.1)
III 30 (19.5)
IV 1 (0.6)
V 0
PD medication treatment
Drug naive 19 (12.3)
Levodopa 45 (29.2)
Dopaminergic agonists 57 (37)
MAOB inhibitor 73 (47.4)
LEDD (mg/day) 178.1  148.2
Motor phenotype
PIGD 78 (50.6)
Indeterminate 13 (8.4)
TD 63 (40.9)
MMSE score 28.6  1.3
MoCA scorea 25.2  3.7
GDS-15 score 2.8  2.6
GDS-15, Geriatric Depression Scale-15; H&Y, Hoehn & Yahr;
LEDD, levodopa equivalent daily dose; MAOB, monoamine oxidase
B; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s
Disease Rating Scale, revised; MMSE, Mini-Mental State Examina-
tion; MoCA, Montreal Cognitive Assessment; PIGD, postural insta-
bility gait difficulty motor subtype; TD, tremor dominant motor
subtype. Data are given as mean  SD, n (%) and median (in-
terquartile range). aMoCA completed in 140 patients with PD.
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compared with TD subtype (203.0  138.6 mg vs.
151.4  165.4 mg, respectively, P < 0.01; Table 4).
Predictors of PIGD motor phenotype were then
determined, first using logistic univariate regression.
Significant predictors included age, LEDD, Geriatric
Depression Scale-15 score, number of pNMS, GI
symptoms and urinary symptoms (Table S1).
Backwards regression revealed that only age
[b = 0.061; odds ratio (OR), 1.06; 95% confidence
interval (CI), 1.02–1.11, P = 0.003] was a significant
predictor of PIGD phenotype; a basic model was then
constructed with age and LEDD. LEDD was included
in the basic model as it was an important confounding
variable although it was not a significant predictor of
PIGD phenotype. Total pNMS and pNMS domains
were then individually added to the model. Analysis
revealed that total pNMS was not a significant predic-
tor of having PIGD phenotype (OR, 1.10; 95% CI,
0.99–1.21 P > 0.05). However, there was a significant
association between any prodromal GI symptoms (OR,
2.30; 95% CI, 1.08–4.89, P < 0.05) and urinary symp-
toms (OR, 2.54; 95% CI, 1.19–5.35, P < 0.05) and the
PIGD phenotype. Patients with PD with prodromal GI
symptoms were thus 2.3 times more likely to develop
Table 2 Prevalence of non-motor symptoms (NMS) at screening and prodromal NMS (pNMS) in patients with Parkinson’s disease (PD) and
median duration before the development of motor symptoms
pNMS
(n = 154)
Time interval of NMS
preceding motor
symptoms (months)
pNMS in males vs. females
Males
(n = 100)
Females
(n = 54) Test statistic P-value
No. of patients with PD with symptoms 139 (90.3)
No pNMS experienced 4 (2–7) 4 (2–6.25) 4 (2–7) U = 2850.5 0.649
Gastrointestinal tract
Sialorrhea 47 (30.5) 33 (18 to 3) 34 (34) 13 (24.1) v2 = 1.6 0.202
Dysphagia 18 (11.7) 25 (27 to 4) 11 (11) 7 (13) v2 = 0.1 0.718
Nausea 3 (1.9) 25 (48 to 24) 1 (1) 2 (3.7) v2 = 1.3 0.247
Constipation 38 (24.7) 108 (105 to 11) 24 (24) 14 (25.9) v2 = 0.1 0.791
Bowel incontinence 4 (2.6) 175 (516 to 1) 2 (5) 2 (3.7) v2 = 0.4 0.526
Incomplete bowel emptying 26 (16.9) 55 (31 to 6) 17 (17 9 (16.7) v2 = <0.1 0.958
Hyposmia 55 (35.7) 148 (218 to 26) 32 (32.0) 23 (42.6) v2 = 1.7 0.191
Weight change (unexplained) 11 (7.1) 13 (12 to 1) 4 (4.0) 7 (13.0) v2 = 4.2 0.039
Urinary tract
Urinary urgency 42 (27.3) 63 (65 to 12) 25 (25) 17 (31.5) v2 = 0.7 0.389
Nocturia 29 (18.8) 82 (78 to 12) 18 (18) 11 (20.4) v2 = 0.1 0.72
Sexual function
Sexual dysfunction 24 (15.6) 89 (87 to 22) 22 (22.0) 2 (3.7) v2 = 8.9 0.003
Impaired libido 15 (9.7) 56 (96 to 18) 12 (12) 3 (5.6) v2 = 1.7 0.198
Cardiovascular
Orthostatic symptoms 28 (18.2) 23 (31 to 2) 20 (20.0) 8 (14.8) v2 = 0.6 0.426
Falls 16 (10.4) 13 (12 to 2) 11 (11.0) 5 (9.3) v2 = 0.1 0.735
Lower limb swelling 17 (11.0) 61 (75 to 8) 10 (10.0) 7 (13.0) v2 = 0.3 0.576
Neuropsychiatric and cognitive
Forgetfulness/memory 50 (32.5) 36 (36 to 8) 38 (38) 12 (22.2) v2 = 4.0 0.046
Impaired concentration 25 (16.2) 37 (33 to 8) 16 (16.0) 9 (16.7) v2 = <0.11 0.915
Anxiety 42 (27.3) 99 (36 to 12) 22 (22.0) 20 (37.0) v2 = 4.0 0.046
Low mood 27 (17.5) 20 (31 to 7) 15 (15) 12 (22.2) v2 = <0.1 0.261
Loss of interest/apathy 22 (14.3) 20 (25 to 8) 13 (13) 9 (16.7) v2 = 0.4 0.535
Delusions 0 (0) NA 0 (0) NA 0 (0) NA NA
Visual hallucinations 12 (7.8) 12 (17 to 4) 7 (7.0) 5 (9.3) v2 = 0.2 0.618
Sleep
Daytime somnolence 32 (20.8) 68 (79 to 12) 25 (25) 7 (13) v2 = 3.1 0.079
Insomnia 10 (6.5) 28 (51 to 11) 5 (5) 5 (9.3) v2 = 1.0 0.306
Dream re-enactment 37 (24.0) 167 (178 to 16) 29 (29.0) 8 (14.8) v2 = 3.9 0.049
Vivid dream imagery 35 (22.7) 175 (228 to 12) 25 (25.0) 10 (18.5) v2 = 0.8 0.36
Restless legs 28 (18.2) 70 (49 to 6) 14 (14.0) 14 (25.9) v2 = 3.4 0.067
Miscellaneous
Diplopia 11 (7.1) 112 (109 to19) 6 (6.0) 5 (9.3) v2 = 0.6 0.454
Hyperhydrosis 4 (2.6) 48 (93 to11) 1 (1.0) 3 (5.6) v2 = 2.9 0.090
Pain (unexplained) 32 (20.8) 15 (23 to6) 17 (17) 15 (27.8) v2 = 2.4 0.116
NA, not applicable. Data are given as n (%) and median (interquartile range).
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
982 R. DURCAN ET AL.
PIGD phenotype, after controlling for age and LEDD.
Similarly, participants with PD with prodromal urinary
symptoms were 2.5 times more likely to evolve into a
PIGD rather than TD phenotype, after controlling for
age and LEDD (Supporting Information).
Discussion
Our study strengthens the notion of NMS antedating
motor symptoms in PD by assessing the presence and
time of onset of the full spectrum of pNMS using a
validated NMS questionnaire (NMSQuest) in a popu-
lation with recently diagnosed PD. Interpretation of
previous studies evaluating the frequency and dura-
tion of onset of pNMS is limited by study method-
ological variability, lack of direct patient evaluation
[2], long duration from PD diagnosis to study enrol-
ment [12], utilization of non-validated, custom-made
NMS questionnaires [13] or studying only limited sub-
sets of the spectrum on pNMS in PD cohorts [14] or
‘at risk’ of PD cohorts [15,16].
Our study found 90% of participants reporting at
least one pNMS, whereas the median number of
pNMS experienced was four. Previous studies have
reported higher prevalence of prodromal symptoms
than our study, probably due to methodological dif-
ferences. A retrospective study conducted via tele-
phone interview with patients with PD and controls,
using a custom-made questionnaire, reported 98.9%
of subjects with PD having one or more prodromal
symptoms but this study incorporated prodromal
motor symptoms as well as pNMS [2]. Similarly,
another retrospective study, with a long mean dura-
tion from PD diagnosis of 7.6  5.6 years, reported
98.9% of subjects experienced prodromal symptoms
preceding a diagnosis of PD [12].
Based on the Braak model of the hypothesized
spread of alpha-synuclein in PD, alpha synuclein
accumulation begins in the gut before progressing via
the vagus nerve to the brain [17]. Therefore, GI fea-
tures should be a prominent early manifestation of
PD. Our study encompassed questions focusing on
the GI tract that had not been previously reported,
such as the prevalence of prodromal weight loss
(7.1%), dysphagia (11.7%) and incomplete bowel
emptying (16.9%). Prevalence of prodromal constipa-
tion symptoms (24.7%) and hyposmia (35.7%) have
previously been reported and are approximately in
Table 3 Prevalence and median duration of prodromal non-motor symptoms (pNMS) according to distinct pNMS domains
Symptom group PD pNMS
Time interval of NMS preceding
motor symptoms (months)
pNMS in males vs. females
Males
(n = 100)
Females
(n = 54) v2 P-value
Gastrointestinal tract 104 (67.5) 58.5 (217 to 16) 67 (67.0) 37 (68.5) <0.1 0.848
Urinary tract 65 (42.2) 45 (126 to 14) 38 (38.0) 20 (37.0) <0.1 0.906
Sexual function 32 (20.8) 60 (119 to 29) 26 (26.0) 3 (5.6) 9.6 0.002
Cardiovascular 50 (32.5) 12 (48 to 5) 35 (35.0) 15 (27.8) 0.8 0.361
Neuropsychiatric and cognitive 19 (12.3) 39 (132 to14) 55 (55) 30 (55.6) <0.1 0.947
Sleep 81 (52.6) 66 (237 to 19) 55 (55.0) 25 (46.3) 1.1 0.302
Miscellaneous 34 (22.1) 12 (48 to 8) 19 (19.0) 22 (40.7) 8.5 0.004
NMS, non-motor symptoms; PD, Parkinson’s disease. Data are given as n (%) and median (interquartile range).
Table 4 Demographics and prevalence of prodromal non-motor symptoms among Parkinson’s disease (PD) motor subtypes
Variable
PIGD
(n = 78)
TD
(n = 63) Test statistic P-value
Gender (male/female) 56 (71.8)/22(28.2) 36 (57.1)/27 (42.9) v2 = 3.3 0.069
Age (years) 68.4 (9.2) 63.6 (10.97) t = 2.7 0.007
Duration of PD (months) 6.2 (4.8) 5.7 (4.4) U = 2376.0 0.737
LEDD (mg/day) 203.04  138.61 151.4  165.4 U = 1684.5 0.001
MMSE score 28.53 (1.3) 28.8 (1.3) U = 2081.0 0.106
MoCA scorea 24.77 (3.6) 25.6 (3.7) U = 1709.0 0.117
GDS-15 score 3.12 (2.4) 2.3 (2.3) U = 1849.5 0.011
MDS-UPDRS III score 26.96 (12.1) 26.2 (12.1) U = 2315.0 0.556
GDS-15, Geriatric Depression Scale-15; LEDD, levodopa equivalent daily dosage; MDS-UPDRS, Movement Disorder Society Unified Parkin-
son’s Disease Rating Scale, revised; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; PIGD, postural instabil-
ity gait difficulty motor subtype; TD, tremor dominant motor subtype. Data are given as mean  SD and n (%) unless otherwise stated.
Significant results are highlighted in bold. aMoCA completed in 140 patients with PD.
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line with published work [2,13]. Clustering prodromal
GI symptoms together revealed that 67.5% of subjects
with PD had one or more GI symptoms antedating
motor symptom development in PD, which is consis-
tent with the Braak model of early GI involvement in
PD. Moreover, GI clusters, as well as urinary tract
clusters, of pNMS were significantly associated with
PIGD motor phenotype. To the best of our knowl-
edge, no other study has shown an association
between pNMS clusters and early PD motor pheno-
type.
In contrast with other studies, the prevalence of
prodromal memory complaints (32.8%) and unex-
plained pain (20.8%) in our study is substantially
higher compared with previous reported work [12,13].
Meanwhile, the prevalence of apathy (14.8%) and
hyperhidrosis (2.6%) is significant lower than in other
studies. The variability in reported prevalence rate of
pNMS may be due to individual’s perception and
reporting of NMS. Many NMS progress slowly and
are of mild severity, so are underappreciated in the
early stages [12]. Furthermore, cognitive impairment
has also been associated with underestimation of NMS
and loss of awareness of hyposmia has been reported
to occur in Parkinson’s disease mild cognitive impair-
ment [18]. It is possible that cognitive performance
may have impacted on symptom recall in our study as
the mean Montreal Cognitive Assessment score was
25.2 (3.7) and previously published work from
the ICICLE-PD study showed that, among the five
cognitive domains, memory impairment was the most
common domain affected in participants with PD at
1.5 SDs below normative values (15.1%) [5]. How-
ever, all participants enrolled in the study underwent
rigorous assessment to exclude dementia.
Gender has been reported as an independent predic-
tor of NMS reported in early PD studies. Females have
been reported to experience more anxiety, pain, depres-
sion and sleep disturbance [19–21], whereas males have
been reported to experience more apathy and sexual
dysfunction [22–24]. However, there is a paucity of
work examining the influence of gender on NMS in
the prodromal period. We found a gender difference
in terms of specific pNMS experienced, namely sexual
dysfunction, forgetfulness and dream re-enactment
being more prevalent in males, and unexplained weight
change and anxiety being more prevalent in females.
Gender differences in perceived pNMS prevalence may
be reflective of what each gender interprets to be
important rather than any underlying early patho-
logical evolutionary difference between genders.
There are some limitations in our study. The retro-
spective design of this study may have introduced
recall error and thereby affected the accuracy of the
data. Attempts were made to minimize recall errors
by having experienced movement disorder physicians
conduct face-to-face interviews with patients with
recently diagnosed PD, including a caregiver inter-
view. Another limitation is the lack of a validated
prodromal questionnaire to evaluate pNMS.
NMSQuest was adapted to identify pNMS as is has
been extensively used to investigate NMS in de-novo,
early PD. However, its sensitivity and specificity for
evaluating prodromal symptoms in ‘at risk’ PD
cohorts have not been established. Therefore, it is
entirely possible that some of the symptoms reported
in this study are not related to an evolving Lewy body
disorder but other underlying medical conditions or
non-specific normal age-related symptoms.
In conclusion, our study has shown that pNMS are
prevalent, antedate motor symptoms in some cases by
several years and distinct gender differences exist in
the pNMS experienced. Furthermore, prodromal GI
and urinary tract symptoms were associated with the
PIGD motor phenotype.
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